OncoCyte Future Growth
Future criteria checks 2/6
OncoCyte's earnings are forecast to decline at 21.1% per annum while its annual revenue is expected to grow at 72.9% per year. EPS is expected to decline by 14.1% per annum.
Key information
-21.1%
Earnings growth rate
-14.1%
EPS growth rate
| Biotechs earnings growth | 35.4% |
| Revenue growth rate | 72.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 24 Aug 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 9 | -28 | N/A | N/A | 1 |
| 12/31/2024 | 5 | -27 | N/A | -7 | 5 |
| 12/31/2023 | 1 | -23 | N/A | -25 | 4 |
| 6/30/2023 | 1 | -17 | -39 | -38 | N/A |
| 3/31/2023 | 1 | -11 | -45 | -42 | N/A |
| 12/31/2022 | 1 | -19 | -50 | -46 | N/A |
| 9/30/2022 | 0 | -30 | -47 | -43 | N/A |
| 6/30/2022 | 0 | -34 | -46 | -43 | N/A |
| 3/31/2022 | 1 | -43 | -42 | -39 | N/A |
| 12/31/2021 | 2 | -44 | -38 | -36 | N/A |
| 9/30/2021 | 5 | -35 | -37 | -35 | N/A |
| 6/30/2021 | 4 | -28 | -32 | -30 | N/A |
| 3/31/2021 | 2 | -26 | -31 | -29 | N/A |
| 12/31/2020 | 1 | -30 | -27 | -26 | N/A |
| 9/30/2020 | 1 | -32 | -27 | -25 | N/A |
| 6/30/2020 | 0 | -30 | -25 | -24 | N/A |
| 3/31/2020 | 0 | -26 | -21 | -20 | N/A |
| 12/31/2019 | N/A | -22 | -21 | -20 | N/A |
| 9/30/2019 | N/A | -19 | -17 | -17 | N/A |
| 6/30/2019 | N/A | -17 | -15 | -14 | N/A |
| 3/31/2019 | N/A | -16 | -16 | -16 | N/A |
| 12/31/2018 | N/A | -16 | -12 | -12 | N/A |
| 9/30/2018 | N/A | -15 | -13 | -13 | N/A |
| 6/30/2018 | N/A | -19 | -14 | -14 | N/A |
| 3/31/2018 | N/A | -18 | -13 | -13 | N/A |
| 12/31/2017 | N/A | -19 | -13 | -13 | N/A |
| 9/30/2017 | N/A | -19 | -13 | -13 | N/A |
| 6/30/2017 | N/A | -14 | -10 | -10 | N/A |
| 3/31/2017 | N/A | -13 | N/A | -9 | N/A |
| 12/31/2016 | N/A | -11 | N/A | -8 | N/A |
| 9/30/2016 | N/A | -12 | N/A | -7 | N/A |
| 6/30/2016 | N/A | -11 | N/A | -7 | N/A |
| 3/31/2016 | N/A | -10 | N/A | -6 | N/A |
| 12/31/2015 | N/A | -9 | N/A | -4 | N/A |
| 9/30/2015 | N/A | -7 | N/A | -3 | N/A |
| 6/30/2015 | N/A | -5 | N/A | -2 | N/A |
| 3/31/2015 | N/A | -5 | N/A | -1 | N/A |
| 12/31/2014 | N/A | -5 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7OC0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 7OC0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 7OC0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 7OC0's revenue (72.9% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 7OC0's revenue (72.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 7OC0's Return on Equity is forecast to be high in 3 years time